LEASE AGREEMENT BETWEEN HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY AND Eurand Pharmaceuticals, Inc. SUITE NO. ___4100Lease Agreement • March 31st, 2008 • Eurand N.V. • Pharmaceutical preparations • Alabama
THIS LEASE AGREEMENT (the “Lease”) is made and entered into on this the 15th day of January, 2008, by and between Hudson-Alpha Institute for Biotechnology, an Alabama non-profit corporation (“Landlord”), and Eurand Pharmaceuticals. Inc a Delaware Corporation (“Tenant”).
DEVELOPMENT AND LICENSE AGREEMENT between Eurand, Inc. And SmithKline Beecham Corporation d/b/a GlaxoSmithKline For aDevelopment and License Agreement • March 31st, 2008 • Eurand N.V. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND LICENSE AGREEMENT dated as of the 21st day of April 2006, (the “Effective Date”) is by and between Eurand, Inc., a Nevada corporation with its principal offices at 845 Center Drive, Vandalia, Ohio 45377 (“Eurand”) and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation with its principal offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102 (“GSK”). Eurand and GSK are sometimes collectively referred to herein as the “Parties” and separately as a “Party”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 31st, 2008 • Eurand N.V. • Pharmaceutical preparations • Pennsylvania
This Securities Purchase Agreement (this “Agreement”) is made and entered into on the 30th day of November, 2007 by and among Michael J. Walters (“Walters”), Norman Stanley (“Stanley”; and together with Walters the “Management Sellers”), Lonnie S. McMillian (“McMillian”), Stoneway LLC, an Alabama limited liability company (“Stoneway”; and together with McMillian, the “Investor Sellers”) and Eurand Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”). The Management Sellers and the Investor Sellers are sometimes referred to herein as the “Sellers”.
